Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer


The content, links, and pdfs are no longer maintained and might be outdated.

  • The content on this page is being archived for historic and reference purposes only.
  • For current, updated information see the MMWR website.

Errata: Vol. 58, No. RR-8

In the report, "Prevention and Control of Seasonal Influenza with Vaccines --- Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009," errors occurred on page 13 in Table 2. The corrected table is printed on the following page.

TABLE 2. Approved influenza vaccines for different age groups --- United States, 2009--10 season

Vaccine

Trade name

Manufacturer

Presentation

Mercury content
(mcg Hg/0.5 mL dose)

Age group

No. of doses

Route

TIV*

Fluzone

Sanofi Pasteur

0.25mL prefilled syringe

0.5 mL prefilled syringe

0.5 mL vial

5.0 mL multidose vial

0

0

0

25

6--35 mos

≥36 mos

≥36 mos

≥6 mos

1 or 2

1 or 2

1 or 2

1 or 2

Intramuscular§

Intramuscular

Intramuscular

Intramuscular

TIV

Fluvirin

Novartis Vaccine

5.0 mL multidose vial 0.5 mL prefilled syringe

25
<1.0

≥4 yrs

1 or 2

Intramuscular

TIV

Fluarix

GlaxoSmithKline

0.5 mL prefilled syringe

0

≥18 yrs

1

Intramuscular

TIV

FluLaval

GlaxoSmithKline

5.0 mL multidose vial

25

≥18 yrs

1

Intramuscular

TIV

Afluria

CSL Biotherapies

0.5 mL prefilled syringe 5.0 mL multidose vial

0

25

≥18 yrs

1

Intramuscular

LAIV

FluMist**

MedImmune

0.2 mL sprayer

0

2--49 yrs

1 or 2††

Intranasal

* Trivalent inactivated vaccine. A 0.5-mL dose contains 15 mcg each of A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Brisbane/ 60/2008-like antigens.

Two doses administered at least 1 month apart are recommended for children aged 6 months--8 years who are receiving TIV for the first time and those who only received 1 dose in their first year of vaccination should receive 2 doses in the following year.

§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

Live attenuated influenza vaccine. A 0.2-mL dose contains 106.5--7.5 fluorescent focal units of live attenuated influenza virus reassortants of each of the three strains for the 2008--09 influenza season: A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), and B/Brisbane/60/2008.

** FluMist is shipped refrigerated and stored in the refrigerator at 2°C--8°C (36°F to 46°F) after arrival in the immunization clinic. The dose is 0.2 mL divided equally between each nostril. FluMist should not be administered to persons with asthma. Health-care providers should consult the medical record, when available, to identify children aged 2--4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving FluMist, parents or caregivers of children aged 2--4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record during the preceding 12 months should not receive FluMist.

†† Two doses administered at least 4 weeks apart are recommended for children aged 2--8 years who are receiving LAIV for the first time, and those who only received 1 dose in their first year of vaccination should receive 2 doses in the following year.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.


References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 8/20/2009

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services